# Clinical Evaluation of 177Lu-DOTA-EB-FAPI in Patients With Various Solid Tumors

> **NCT05963386** · PHASE2 · COMPLETED · sponsor: **The First Affiliated Hospital of Xiamen University** · enrollment: 28 (actual)

## Conditions studied

- Refractory Solid Tumor

## Interventions

- **DRUG:** 177Lu-DOTA-EB-FAPI radionuclide therapy

## Key facts

- **NCT ID:** NCT05963386
- **Lead sponsor:** The First Affiliated Hospital of Xiamen University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-02-22
- **Primary completion:** 2024-09-15
- **Final completion:** 2024-10-05
- **Target enrollment:** 28 (ACTUAL)
- **Last updated:** 2025-03-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05963386

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05963386, "Clinical Evaluation of 177Lu-DOTA-EB-FAPI in Patients With Various Solid Tumors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05963386. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*